权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Usefulness of continuous porous hydroxyapatite ceramics with bone marrow stromal cells

连续多孔羟基磷灰石陶瓷与骨髓基质细胞的用途

基本信息

批准号：
14370672
负责人：
UEYAMA Yoshiya
金额：
$ 8.58万
依托单位：
Yamaguchi University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2004
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14370672/
关键词：
continuous porous hydroxyapataite ceramic bone marrow stromal cell bone regeneration

项目摘要

1.The continuous porous hydroxyapatite ceramics (cp-HA) consisted of β-tricalcium phosphate (β-TCP) known as bone displacement materials, and α-tricalcium phosphate (α-TCP) as a thermophile stable phase, and it's characteristics is that the porosity was about 85mm, and the pore diameter was about 0.8mm. Furthermore, we tried making of a cp-HA which lowered pore diameter by the range that osteoblast could infiltrate as much as possible to add to intensity, but pore was clogged up by surface tension of suspension to dip a soft firing polyurethane form to 10% silicon dioxide component apatite suspension by manufacture methods of the cp-HA which we used by this study, and the manufacture of lower than porous diameter 0.8mm cp-HA was impossible. Therefore the experiment was used cp-HA of pore diameter 1.0mm and 0.8mm.2.In a difference (1.0mm and 0.8mm) of the pore diameter used for the experiment, the difference was not found in ossiferous quantity and bone formation rate. It is thought that this is not different in an invasion of osteoblast to pores in a difference of porous diameter of this level. But a cp-HA whose pore diameter is massive becomes fragile, then it is not used for clinic. In addition, we confirmed that cpHA contacted new bone directly without connective tissue in pore, but cp-HA did not resorb in vivo and was not replaced by bone.3.In order to make cp-HA included BMSC, it was necessary to mix fibrinogen with BMSC. The difference of quantity of new bone was not confirmed in a condition of cp-HA included BMSC and cp-HA only in 6 months and 12 months, namely a middle long term, in vivo. However, it is though that the experiment in a short term will need in future because the effect of a BMSC component may appear earlier.

1.以β-磷酸三钙(β-tCP)为骨置换材料，α-磷酸三钙(α-tCP)为稳定相的连续多孔羟基磷灰石陶瓷(cp-HA)，其特点是孔隙率约为85 mm，孔径约为0.8 mm。此外，我们还尝试用本研究所用的cp-HA的制备方法，在成骨细胞可以渗透的范围内尽量降低孔径以增加强度，但由于悬浮液的表面张力堵塞了孔洞，将软烧的聚氨酯形式浸渍到10%二氧化硅成分的磷灰石悬浮液中，不可能制备出孔径小于0.8 mm的cp-HA。因此，本实验选用了孔径为1.0 mm和0.8 mm的cp-HA。在实验所用的孔径不同(1.0 mm和0.8 mm)的情况下，骨量和骨形成率没有差异。人们认为，这与成骨细胞对毛孔的侵袭并无不同，只是孔隙直径的不同而不同。但孔径较大的cp-HA会变得易碎，不能用于临床。此外，我们还证实了cp-HA直接与新骨接触，没有孔内结缔组织，但cp-HA在体内没有吸收，也没有被骨替代。3.为了使cp-HA包含BMSC，有必要将纤维蛋白原与BMSC混合。在体内，cp-HA仅在6个月和12个月，即中长期条件下，未证实cp-HA包括BMSC和cp-HA的情况下新生骨数量的差异。然而，由于BMSC成分的作用可能会更早出现，因此短期内的实验将需要在未来进行。